LUSAMA

Posology The recommended dose of Lusama is 20 micrograms administered once daily. 4). The 24-month course of Lusama should not be repeated over a patient’s lifetime. Patients should receive supplemental calcium and vitamin D supplements if dietary intake is inadequate.

Following cessation of Lusama therapy, patients may be continued on other osteoporosis therapies. ). In patients with moderate renal impairment, Lusama should be used with caution. No special caution is required for patients with mild renal impairment.

3). Therefore, teriparatide should be used with caution. Pediatric population and young adults with open epiphyses The safety and efficacy of Lusama in children and adolescents less than 18 years has not been established. Lusama should not be used in paediatric patients (less than 18 years), or young adults with open epiphyses.

2). Method of administration Lusama should be administered once daily by subcutaneous injection in the thigh or abdomen. Before first use of the pen, a priming dose must be released. 6). A user manual is also available to instruct patients on the correct use of the pen.

Summary of the safety profile The most commonly reported adverse reactions in patients treated with teriparatide are nausea, pain in limb, headache and dizziness. 5 % of the placebo patients reported at least 1 adverse event. The adverse reactions associated with the use of teriparatide in osteoporosis clinical trials and post-marketing exposure are summarised in the table below.

The following convention has been used for the classification of the adverse reactions: very common (≥ 1/10), common (≥ 1/100 to <1/10), uncommon (≥ 1/1,000 to <1/100), rare (≥ 1/10,000 to <1/1,000) very rare (<1/10,000). 25 mmol/L Psychiatric disorders Common: Depression Musculoskeletal and connective tissue disorders Very common: Pain in limb Common: Muscle cramps Uncommon: Myalgia, arthralgia, back cramp/pain* Nervous system disorders Common: Dizziness, headache, sciatica, syncope Renal and urinary disorders Uncommon: Urinary incontinence, polyuria, micturition urgency, nephrolithiasis Rare: Renal failure/impairment Ear and labyrinth disorders Common: Vertigo General disorders and administration site conditions Common: Fatigue, chest pain, asthenia, mild and transient injection site events, including pain, swelling, erythema, localised bruising, pruritis and minor bleeding at injection site.

Uncommon:

Injection site erythema, injection site reaction Rare: Possible allergic events soon after injection: acute dyspnoea, oro/facial oedema, generalised urticaria, chest pain, oedema (mainly peripheral).

Cardiac disorders Common:

Palpitations Uncommon: Tachycardia Investigations Uncommon: Weight increased, cardiac murmur, alkaline phosphatase increase Vascular disorders Common: Hypotension *Serious cases of back cramp or pain have been reported within minutes of the injection.

Description of selected adverse reactions In clinical trials the following reactions were reported at a ≥ 1 % difference in frequency from placebo: vertigo, nausea, pain in limb, dizziness, depression, dyspnoea. Teriparatide increases serum uric acid concentrations.

7 % of placebo patients. However, the hyperuricemia did not result in an increase in gout, arthralgia, or urolithiasis. 8 % of women receiving teriparatide. Generally, antibodies were first detected following 12 months of treatment and diminished after withdrawal of therapy.

There was no evidence of hypersensitivity reactions, allergic reactions, effects on serum calcium, or effects on Bone Mineral Density (BMD) response. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Serum and urine calcium In normocalcaemic patients, slight and transient elevations of serum calcium concentrations have been observed following teriparatide injection. Serum calcium concentrations reach a maximum between 4 and 6 hours and return to baseline by 16 to 24 hours after each dose of teriparatide.

Therefore, if blood samples for serum calcium measurements are taken, this should be done at least 16 hours after the most recent Lusama injection. Routine calcium monitoring during therapy is not required. Teriparatide may cause small increases in urinary calcium excretion, but the incidence of hypercalciuria did not differ from that in the placebo-treated patients in clinical trials.

Urolithiasis Teriparatide has not been studied in patients with active urolithiasis. Teriparatide should be used with caution in patients with active or recent urolithiasis because of the potential to exacerbate this condition. Orthostatic hypotension In short-term clinical studies with teriparatide, isolated episodes of transient orthostatic hypotension were observed.

Typically, an event began within 4 hours of dosing and spontaneously resolved within a few minutes to a few hours. When transient orthostatic hypotension occurred, it happened within the first several doses, was relieved by placing subjects in a reclining position, and did not preclude continued treatment.

Renal impairment Caution should be exercised in patients with moderate renal impairment. 1). Treatment should only be initiated if the benefit clearly outweighs risks in this population. Women of childbearing potential should use effective methods of contraception during use of Lusama.

If pregnancy occurs, Lusama should be discontinued. 3). Until further clinical data become available, the recommended treatment time of 24 months should not be exceeded.

1. 6) • Pre-existing hypercalcaemia • Severe renal impairment • Metabolic bone diseases (including hyperparathyroidism and Paget’s disease of the bone) other than primary osteoporosis or glucocorticoid-induced osteoporosis. • Unexplained elevations of alkaline phosphatase • Prior external beam or implant radiation therapy to the skeleton • Patients with skeletal malignancies or bone metastases should be excluded from treatment with teriparatide.